Author:
Liao E. Y.,Luo X. H.,Su X.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference17 articles.
1. Turner R.T., Riggs B.L., Spelsberg T.C. Skeletal effects of estrogen. Endocr. Rev. 1994, 16: 275–300.
2. MacNamara P., O’Shaughnessy C., Manduca P., Loughrey H.C. Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. Calcif. Tissue Int. 1995, 57: 436–441.
3. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 1998, 95: 3597–602.
4. Yasuda H., Shima N., Nakagawa N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139: 1329–1337.
5. Tomoyasu A., Goto M., Fujise N., et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem. Biophys. Res. Commun. 1998, 273: 5117–5123.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献